(HealthDay)—Teprotumumab is associated with better outcomes than placebo among patients with active thyroid eye disease, according to a study published in the Jan. 23 issue of the New England Journal of Medicine. Raymond S. Douglas, M.D., Ph.D., from the Cedars-Sinai…